Find clinical trials in your area

Search by disease and location to discover available clinical trials matching your criteria.

Matched clinical trials

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Estonia France Germany Ireland Italy +1
  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    1 1 1 1
    Hungary Poland Portugal Romania
  • A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

    Recruiting

    1 1
    France Italy Poland Spain
  • A study testing BNT326 and BNT327 with drug combination for safety and effectiveness in people with advanced non-small cell lung cancer

    Recruiting

    1 1 1
    Germany Italy Poland Spain
  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Belgium Bulgaria France Germany Hungary Italy +3
  • Study on Tislelizumab and Chemotherapy for Patients with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Italy
  • Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    France
  • Study of Durvalumab with chemotherapy (paclitaxel, cisplatin, carboplatin, vinorelbine) in patients with stage IIIA/B non-small cell lung cancer that can be removed by surgery

    Recruiting

    1 1 1
    Germany
  • Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    France Greece Hungary Poland
  • Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany